Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascendis Pharma A/S - Ordinary Share
(NQ:
ASND
)
246.35
+0.50 (+0.20%)
Delayed Quote
Updated: 12:48 PM EDT, Oct 28, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascendis Pharma A/S - Ordinary Share
< Previous
1
2
3
4
5
6
7
8
9
Next >
A Look Ahead: Ascendis Pharma's Earnings Forecast
↗
November 11, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
↗
October 29, 2025
Via
Benzinga
Looking Into Ascendis Pharma AS's Recent Short Interest
↗
October 21, 2025
Via
Benzinga
Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis
↗
October 14, 2025
Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum.
Via
Chartmill
What Does the Market Think About Ascendis Pharma AS?
↗
September 29, 2025
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which...
Via
Benzinga
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
September 25, 2025
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market...
Via
Benzinga
How Do Investors Really Feel About Ascendis Pharma?
↗
August 28, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Peering Into Ascendis Pharma's Recent Short Interest
↗
July 03, 2025
Via
Benzinga
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
↗
September 08, 2025
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.
Via
Benzinga
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
↗
September 08, 2025
Via
Benzinga
Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
September 04, 2025
Via
Benzinga
ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum
↗
September 01, 2025
Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance.
Via
Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
August 19, 2025
Via
Benzinga
Is Ascendis Pharma Gaining or Losing Market Support?
↗
June 03, 2025
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
May 29, 2025
Via
Benzinga
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
A Glimpse of Ascendis Pharma's Earnings Potential
↗
April 30, 2025
Via
Benzinga
Ascendis (ASND) Q2 2025 Earnings Call Transcript
↗
August 07, 2025
Via
The Motley Fool
Topics
Earnings
What's Driving the Market Sentiment Around Ascendis Pharma?
↗
August 06, 2025
Via
Benzinga
What's Driving the Market Sentiment Around Ascendis Pharma?
↗
August 04, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
July 28, 2025
Via
Benzinga
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
↗
July 22, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
July 07, 2025
Via
Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
↗
June 12, 2025
Via
Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
↗
May 21, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years
↗
May 06, 2025
Via
Benzinga
This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
↗
May 05, 2025
Via
Benzinga
Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria
↗
April 28, 2025
A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?
Via
Chartmill
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
↗
April 15, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
